Alpha-Synuclein Monoclonal Antibody

$Lane 1: Human Brain lysates; Lane 2: Mouse Brain lysates probed with Alpha-Synuclein; Monoclonal Antibody, Unconjugated (bsm-51696M) at 1:2000 dilution and 4\u02daC overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37\u02daC.$

Lane 1: Human Brain lysates; Lane 2: Mouse Brain lysates probed with Alpha-Synuclein; Monoclonal Antibody, Unconjugated (bsm-51696M) at 1:2000 dilution and 4\u02daC overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37\u02daC.

Applications

Predicted Reactivity

Human
Mouse

Overview
Catalog #	bsm-51696m
Product Name	Alpha-Synuclein Monoclonal Antibody
Applications	WB
Predicted Reactivity	Human, Mouse
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	Recombinant human Alpha-synuclein.
Clonality	Monoclonal
Clone #	H6T1
Concentration	0.5ug/ul
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	6622
Swiss Prot	P37840
Subcellular location	Cytoplasm, Nucleus, Cell membrane
Synonyms	SNCA; SYUA_HUMAN; Alpha synuclein; Alpha-synuclein, isoform NACP140; alpha SYN; MGC105443; MGC110988; MGC127560; MGC64356; NACP; Non A beta component of AD amyloid; Non A4 component of amyloid precursor; Non-A-beta component of alzheimers disease amyloid , precursor of; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; PARK 1; PARK 4; PARK1; PARK4; Parkinson disease (autosomal dominant, Lewy body) 4; Parkinson disease familial 1; Syn; Snca synuclein, alpha (non A4 component of amyloid precursor); Synuclein alpha; Synuclein, alpha (non A4 component of amyloid precursor); Synuclein-?; Synuclein ?.
Background	May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.
Application Dilution
WB	=1:500-2000